GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 11
- 13F valueReported value at the end of Q2 2026
- $164.7K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GRI, Q2 2026
No superinvestor reported holding GRI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by GRI Bio, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by GRI Bio, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in GRI Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HRT Financial LP | 28,784 | $50.0K | 0.00% | +28,784 | New |
| Vanguard Capital Management LLC | 21,368 | $37.8K | 0.00% | +21,368 | New |
| Geode Capital Management, LLC | 13,869 | $24.5K | 0.00% | −4,569−24.8% | Reduced |
| Citadel Advisors LLC | 13,376 | $23.7K | 0.00% | +13,376 | New |
| Morgan Stanley | 8,737 | $15.5K | 0.00% | +8,737 | New |
| UBS Group AG | 4,920 | $8.71K | 0.00% | −3,802−43.6% | Reduced |
| Tower Research Capital LLC (TRC) | 2,434 | $4.31K | 0.00% | +1,374+129.6% | Added |
| Barclays PLC | 83 | $147 | 0.00% | +83 | New |
| BlackRock, Inc. | 7 | $12 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 2 | $4 | 0.00% | 00.0% | Unchanged |